Therapeutic Technologies
The department advances innovative therapeutic technologies by testing novel antibody combinations, targeted delivery systems, and emerging biologics to improve patient outcomes.
- Combination immunotherapy with chemotherapy
- Novel antibody‑drug strategies
- Advanced infusion therapies
- Safety monitoring of emerging biologics
Hospital Paul Brousse in Villejuif, France, supports 11 clinical trials led by 28 investigators, fostering cutting‑edge research in therapeutic innovation.
Digestive System Diseases
Researchers focus on liver‑related conditions, addressing diseases such as Primary Biliary Cholangitis and Alpha‑1 Antitrypsin Deficiency to alleviate symptoms and limit progression.
- Biliary tract cancer treatment
- Management of cholestatic itching
- Fibrosis reduction strategies
- Liver transplantation immunosuppression
The site’s multidisciplinary team conducts trials that integrate gastroenterology expertise with advanced diagnostic tools.
Neoplasms
The oncology program evaluates therapies for liver malignancies, including Hepatocellular Carcinoma and Advanced Biliary Tract Cancers, aiming to extend survival and improve quality of life.
- Immunotherapy plus TACE
- Neoadjuvant regimens for resectable tumors
- Dual checkpoint inhibition
- Targeted anti‑angiogenic combinations
Collaborative studies at Hospital Paul Brousse bring together surgical, radiologic, and medical oncology expertise.
Nutritional and Metabolic Diseases
Clinical investigations target rare metabolic liver disorders such as Urea Cycle Disorders and Crigler‑Najjar Syndrome, exploring cell‑based and gene‑silencing approaches.
- Cell‑based liver support therapies
- Metabolic correction via gene‑silencing
- Long‑term safety of stem‑cell infusions
- Metabolic disease monitoring
These studies integrate metabolic genetics with hepatology to address unmet therapeutic needs.
Behavioral Addictions
The psychiatry division investigates treatments for Behavioral Addictions such as gambling, sexual, and food compulsions, evaluating medications that reduce craving intensity.
- Craving reduction with adjunct medication
- Psychological outcome measures
- Addiction severity scales
- Integration with standard care
The trials aim to expand therapeutic options for patients struggling with compulsive behaviors.
General Clinical Research
A broad portfolio of multicentre investigations supports cross‑disciplinary studies, from safety profiling to biomarker discovery, enhancing overall clinical knowledge.
- Safety profiling across disease groups
- Biomarker discovery
- Patient‑reported outcome tools
- Health‑technology assessments
Hospital Paul Brousse leverages its extensive investigator network to conduct diverse and impactful research.
